000062834 001__ 62834
000062834 005__ 20190709135433.0
000062834 0247_ $$2doi$$a10.1056/NEJMoa1701488
000062834 0248_ $$2sideral$$a99071
000062834 037__ $$aART-2017-99071
000062834 041__ $$aeng
000062834 100__ $$aRidker, P.M.
000062834 245__ $$aCardiovascular efficacy and safety of bococizumab in high-risk patients
000062834 260__ $$c2017
000062834 5060_ $$aAccess copy available to the general public$$fUnrestricted
000062834 5203_ $$aBACKGROUND Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27, 438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of =70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of =100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients.
000062834 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000062834 590__ $$a79.258$$b2017
000062834 591__ $$aMEDICINE, GENERAL & INTERNAL$$b1 / 154 = 0.006$$c2017$$dQ1$$eT1
000062834 592__ $$a19.476$$b2017
000062834 593__ $$aMedicine (miscellaneous)$$c2017$$dQ1
000062834 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000062834 700__ $$aRevkin, J.
000062834 700__ $$aAmarenco, P.
000062834 700__ $$aBrunell, R.
000062834 700__ $$aCurto, M.
000062834 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000062834 700__ $$aFlather, M.
000062834 700__ $$aGlynn, R.J.
000062834 700__ $$aGregoire, J.
000062834 700__ $$aJukema, J.W.
000062834 700__ $$aKarpov, Y.
000062834 700__ $$aKastelein, J.J.P.
000062834 700__ $$aKoenig, W.
000062834 700__ $$aLorenzatti, A.
000062834 700__ $$aManga, P.
000062834 700__ $$aMasiukiewicz, U.
000062834 700__ $$aMiller, M.
000062834 700__ $$aMosterd, A.
000062834 700__ $$aMurin, J.
000062834 700__ $$aNicolau, J.C.
000062834 700__ $$aNissen, S.
000062834 700__ $$aPonikowski, P.
000062834 700__ $$aSantos, R.D.
000062834 700__ $$aSchwartz, P.F.
000062834 700__ $$aSoran, H.
000062834 700__ $$aWhite, H.
000062834 700__ $$aWright, R.S.
000062834 700__ $$aVrablik, M.
000062834 700__ $$aYunis, C.
000062834 700__ $$aShear, C.L.
000062834 700__ $$aTardif, J.C.
000062834 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000062834 773__ $$g376, 16 (2017), 1527-1539$$pN. Engl. j. med.$$tNEW ENGLAND JOURNAL OF MEDICINE$$x0028-4793
000062834 8564_ $$s639727$$uhttps://zaguan.unizar.es/record/62834/files/texto_completo.pdf$$yVersión publicada
000062834 8564_ $$s98201$$uhttps://zaguan.unizar.es/record/62834/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000062834 909CO $$ooai:zaguan.unizar.es:62834$$particulos$$pdriver
000062834 951__ $$a2019-07-09-11:32:54
000062834 980__ $$aARTICLE